子宫内膜癌:妇科肿瘤学会循证综述与推荐
本文为妇科肿瘤学会(SGO)发布的子宫内膜癌循证综述与推荐。文章指出尽管诊治手段进步,1987至2014年间子宫内膜癌病例增加75%、死亡增加近300%;综述涵盖分子病理、遗传易感性、淋巴结评估、放化疗疗效及生存随访进展,并由专家面板按ASCCP两级评分系统给出推荐。
要点
- 1987至2014年子宫内膜癌病例增加75%,死亡增加近300%。
- 综述涵盖分子病理、遗传易感性、淋巴结评估、放化疗及生存随访进展。
- 推荐由SGO临床实践与教育委员会专家面板制定,采用ASCCP两级评分系统。
核心结论
- 尽管诊治手段进步,子宫内膜癌发病与死亡仍在上升,需综合应用分子病理、遗传评估、淋巴结评估及放化疗等进展优化诊疗。
研究设计与样本
- 妇科肿瘤学会(SGO)临床实践与教育委员会专家面板对现有证据进行综述并制定推荐,经SGO临床实践委员会、出版委员会及董事会批准。
主要发现
- 1987至2014年间子宫内膜癌病例增加75%,死亡增加近300%。
- 进展包括分子病理应用增加、遗传易感性认识加深、淋巴结评估方法改进、放化疗疗效理解拓宽及生存随访方法更高效。
关键数值与推荐
- 推荐条款采用ASCCP管理指南的两级评分系统,分别对推荐强度和证据质量进行分级,每条推荐后括号内给出评分。
临床怎么用
- 临床可参考本综述整合分子病理、遗传评估、淋巴结评估及放化疗证据,按分级推荐优化子宫内膜癌诊疗与随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In 2014, the Society of Gynecologic Oncology's Clinical Practice Committee published a clinical update reviewing the treatment of women with endometrial cancer. At that time, there had been significant advances in the diagnosis, work-up, surgical management, and available treatment options allowing for more optimal care of affected women. Despite these advances, the incidence of endometrial cancer as well as the deaths attributable to the disease have continued to rise; from 1987 to 2014 there has been a 75% increase in cases and almost 300% increase in endometrial cancer deaths. Fortunately, since then, there has been progress in the treatment of patients with endometrial cancer with increased utilization of molecular pathology, greater understanding of genetic predisposition, enhanced methods for lymph node assessment, a broader understanding of the efficacy of radiation and chemotherapy, and a more efficient approach to survivorship and surveillance. The purpose of this document is to present a comprehensive review of this progress. MANUSCRIPT DEVELOPMENT PROCESS: The authors reviewed the available evidence, contributed to the development of this manuscript, provided critical review of the guidelines, and finalized the manuscript recommendations. The review was also presented to and approved by the Society of Gynecologic Oncology (SGO) Clinical Practice Committee, SGO Publications Committee, and the SGO board members prior to submission for publication. The recommendations for this manuscript were developed by a panel of gynecologic oncologists who were members of the SGO Clinical Practice and Education Committees. Panelists reviewed and considered evidence from current uterine cancer literature. The terminology used in these guidelines was adopted from the ASCCP management guidelines [1] using a two-part rating system to grade the strength of recommendation and quality of evidence (Table 1). The rating for each recommendation is given in parentheses.
引用
- Hamilton CA, Pothuri B, Arend RC, et al. Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations. Gynecol Oncol. 2021. PMID: 33516529. doi:10.1016/j.ygyno.2020.12.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。